Cargando…

Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer

BACKGROUND: Protein phosphatase 2A (PP2A) is a tumour suppressor frequently inactivated in human cancer and its tyrosine-307 phosphorylation has been reported as a molecular inhibitory mechanism. METHODS: Expression of phosphorylated PP2A (p-PP2A) was evaluated in 250 metastatic colorectal cancer (C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cristóbal, I, Manso, R, Rincón, R, Caramés, C, Zazo, S, del Pulgar, T G, Cebrián, A, Madoz-Gúrpide, J, Rojo, F, García-Foncillas, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134505/ https://www.ncbi.nlm.nih.gov/pubmed/25003662 http://dx.doi.org/10.1038/bjc.2014.376

Ejemplares similares

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy
por: del Puerto-Nevado, L, et al.
Publicado: (2014)

Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
por: Madoz-Gúrpide, Juan, et al.
Publicado: (2015)

Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer
por: Cristóbal, Ion, et al.
Publicado: (2016)

Potential therapeutic value of miR‐425‐5p in metastatic colorectal cancer
por: Cristóbal, Ion, et al.
Publicado: (2016)

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects
por: Rincón, Raúl, et al.
Publicado: (2015)

Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer
por: Cristóbal, Ion, et al.
Publicado: (2019)

Expression of Phosphorylated BRD4 Is Markedly Associated with the Activation Status of the PP2A Pathway and Shows a Strong Prognostic Value in Triple Negative Breast Cancer Patients
por: Sanz-Álvarez, Marta, et al.
Publicado: (2021)

MicroRNA-199b Deregulation Shows a Strong SET-Independent Prognostic Value in Early-Stage Colorectal Cancer
por: Cristóbal, Ion, et al.
Publicado: (2020)

Deregulation of the miR-19b/PPP2R5E Signaling Axis Shows High Functional Impact in Colorectal Cancer Cells
por: Santos, Andrea, et al.
Publicado: (2023)

Low MicroRNA-19b Expression Shows a Promising Clinical Impact in Locally Advanced Rectal Cancer
por: Rubio, Jaime, et al.
Publicado: (2021)

Validation of microRNA-199b as A Promising Predictor of Outcome and Response to Neoadjuvant Treatment in Locally Advanced Rectal Cancer Patients
por: Cristóbal, Ion, et al.
Publicado: (2021)

MicroRNA-19b Plays a Key Role in 5-Fluorouracil Resistance and Predicts Tumor Progression in Locally Advanced Rectal Cancer Patients
por: Santos, Andrea, et al.
Publicado: (2022)

Comment on ‘TAp63 suppress metastasis via miR-133b in colon cancer cells'
por: Cristobal, I, et al.
Publicado: (2014)

MicroRNA-199b Downregulation Confers Resistance to 5-Fluorouracil Treatment and Predicts Poor Outcome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients
por: Cristóbal, Ion, et al.
Publicado: (2020)

Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer
por: Chamizo, Cristina, et al.
Publicado: (2015)

Comment on ‘MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells’
por: Cristóbal, Ion, et al.
Publicado: (2017)

Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma
por: Rojo, Federico, et al.
Publicado: (2016)

MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines
por: Arriola, E, et al.
Publicado: (2011)

Functional and Clinical Impact of CircRNAs in Oral Cancer
por: Cristóbal, Ion, et al.
Publicado: (2020)

Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer
por: Rao, S R, et al.
Publicado: (2017)

CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer
por: Luque, Melani, et al.
Publicado: (2022)

Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers
por: Takahashi, Y, et al.
Publicado: (2014)

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
por: Souglakos, J, et al.
Publicado: (2009)

RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas
por: Deb, S, et al.
Publicado: (2014)

Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis
por: Goos, J A C M, et al.
Publicado: (2013)

Stable interference of EWS–FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target
por: Herrero-Martín, D, et al.
Publicado: (2009)

Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer
por: Larsson, A, et al.
Publicado: (2011)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival
por: Herath, N I, et al.
Publicado: (2009)

Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer
por: Carpenter, B, et al.
Publicado: (2006)

Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma
por: González-Alonso, Paula, et al.
Publicado: (2015)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity
por: Gooden, M J M, et al.
Publicado: (2014)

Feasibility of proposed single-nucleotide polymorphisms as predictive markers for targeted regimens in metastatic colorectal cancer
por: Kim, J C, et al.
Publicado: (2013)

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
por: Oden-Gangloff, A, et al.
Publicado: (2009)

MicroRNA-199b Deregulation Shows Oncogenic Properties and Promising Clinical Value as Circulating Marker in Locally Advanced Rectal Cancer Patients
por: Santos, Andrea, et al.
Publicado: (2022)

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
por: Schirripa, M, et al.
Publicado: (2015)

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
por: Frattini, M, et al.
Publicado: (2007)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer
por: Vreuls, C P H, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_geoj0mhak97u4qta0gjs4jimlg